

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1430 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/542,088	07/13/2005	Jurgen Braunger	26797U	1055
34375 NATH & ASS	7590 05/21/200 OCIATES PLLC	EXAMINER		
112 South We	st Street		PAGONAKIS, ANNA	
Alexandria, V.	A 22314		ART UNIT	PAPER NUMBER
			1614	
			MAIL DATE	DELIVERY MODE
			05/21/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/542,088	BRAUNGER ET AL.		
Examiner	Art Unit		
ANNA PAGONAKIS	1614		

	ANNA PAGONAKIS	1614						
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress					
THE REPLY FILED 24 February 2009 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.						
☑ The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or ofter evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 3 To F4.1.3.1; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:								
	The period for reply expiresmonths from the mailing date of the final rejection.							
no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (he period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In o event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. xaminer Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO							
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(26(a) and the annualist	o outonalan foo					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filled, may reduce any earned patent term adjustment. See 37 CFR 1.794(b).								
NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of								
The Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(b), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS								
	t prior to the data of Elina a brief							
 The proposed amendment(s) flied after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); 								
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or								
(d) ☐ They present additional claims without canceling a c NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	ected claims.						
4. The amendments are not in compliance with 37 CFR 1.12		mpliant Amendment (PTOL-324).					
5. Applicant's reply has overcome the following rejection(s):								
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		•						
	7. ☐ For purposes of appeal, the proposed amendment(s): a) ☐ will not be entered, or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.							
Claim(s) allowed:								
Claim(s) objected to:								
Claim(s) rejected: <u>86-94</u> . Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE								
The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).								
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons wity it is necessary and was not earlier presented. See 37 CFR 430(1).								
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER								
11. 🔀 The request for reconsideration has been considered but does NOT place the application in condition for allowance because:								
See Continuation Sheet. 12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)								
13. Other:								
/Ardin Marschel/ Supervisory Patent Examiner, Art Unit 1614	/Anna Pagonakis/ Examiner, Art Unit 1614							

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

THIS ADVISORY ACTION MAILED ON FEBRUARY 14, 2009 IS HEREBY VACATED AND REPLACED WITH THE CURRENT ADVISORY ACTION. THE CURRENT ADVISORY ACTION SETS FORTH THE APPROPRIATE REPLY PERIOD.

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant's remarks presented in the after-final amendment regarding the 103 rejection has been considered and entered into the record but are not persuasive.

Applicant traverse the rejection on the grounds that Gaspar Elsas et al describe a significant decrease in the total number of myeloid colonies after administration of rolipram in normal, healthy myeloid progenitor cells derived from the bone marrow in vitro. Further, applicant alleges that neither Reid nor Sacchi et al. nor Zhao et al describe the use of roflumilast and ATRA, either alone or in combination for the treatment of AMIL.

With regard to Applicant's allegation that one would not be motivated to administer rolipram to diseased myeloid colonies, this is unpersuasive. Given that significant decrease in colonies, one would be motivated to administer the elected colonies, this is uppersuably of the property o

In the absence of any additional evidence or argumetrs the rejection remains proper and is maintained.